• About
• Links
• Contact
• Sitemap

World Neurodegeneratives Disease Markets, 2005-2009

 

Table of Contents

• 1.Introducing the World Market for Neurodegenerative Disorders

Table 1.1 Overall Forecast for Neurodegenerative Market ($bn), 2002 - 2009

Graph 1.1 Total revenues for Neurodegenerative diseases ($bn) 2002 - 2009

Graph 1.2 Annual Growth Rate for ND Market 2002 - 2009

Chart 1.1 The Market Share (%) for ND diseases 2003

Chart 1.2 Market Share (%) for the ND, 2009

• 2. Neurodegenerative Disorders
  • 2.1 Introduction to Neurodegenerative Disorders
  • 2.2 What the Global Market for Neurodegenerative Disorders tells us
  • 2.3 Focus of the report
• 3. Parkinson's Disease
  • 3.1 Parkinson's Disease Overview
  • 3.2 Symptoms and Differential Diagnosis
    • 3.2.1 Tremors
    • 3.2.2 Bradykinesia
    • 3.2.3 Diagnosis
  • 3.3 What are the Risk Factors?
    • 3.3.1 Age
    • 3.3.2 A possible genetic basis to PD
    • 3.3.3 Men are more likely to develop PD
    • 3.3.4 Pesticides and Herbicides influence PD Development
    • 3.3.5 Reduced Oestrogen Levels Increase the Risk of PD
    • 3.3.6 Reduced Folate Levels Associated with PD
  • 3.4 Demographics of PD

Table 3.1 Demographic Facts of PD Worldwide

• 3.5 Financial Burden of PD
• 3.6 Pathophysiology of PD
• 3.7 The Market Profile of PD
• 3.8 Current Pharmaceutical Therapies of PD

Table 3.2 Current Pharmaceutical Therapies for PD, 2003

• 3.9 Dopamine Precursers as the Standard Treatments for PD
  • 3.9.1 Sinemet (Co-careldopa)
  • 3.9.2 Madopar (Co-benelopa)
  • 3.9.3 Carbidopa and Benserazide
• 3.10 Dopamine Agonists as Treatments for PD
  • 3.10.1 Ergot-Alkaloid-Based Agents
  • 3.10.2 Parlodel (Bromocriptine)
  • 3.10.3 Dopergine (lisuride) is Superior to Parlodel
  • 3.10.4 Permax (pergolide)
• 3.11 Apomorphine as Additional Relief for PD Sufferers
  • 3.11.1 Requip (Ropinirole)
  • 3.11.2 Sifrol/Mirapexin (Pramipexole) is the Most Successful Drug in PD
• 3.12 N-Methyl-D-Asparate Receptor Antagonists (NMDA)
• 3.13 Symmetrel (Amantadine)
• 3.14 AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Receptor

Antagonist

• 3.14.1 Talampanel
• 3.15 COMT (cateh-o-methyl-transferase)
  • 3.15.1 Tasmar (Tolcapone) as an Adjunct Therapy
  • 3.15.2 Comptess (Entacaopne)to Aid PD Treatment
• 3.16 Dopamine and COMT Combined
  • 3.16.1 Stalevo (Careldopa)
• 3.17 Anticholinergics (Antimuscarnic drugs)
  • 3.17.1 Congentin (benzatropine mesilate)
  • 3.17.2 Artane (Trihexyphenidyl) to Control Common Symptoms
• 3.18 Antihistamines and Antidepressants can Aid PD Symptoms
• 3.19 Monoamine Oxidase B Inhibitors
• 3.20 The World Market for PD Drugs will Show Significant Growth to 2009

Table 3.3 Global revenues ($bn) for PD Drugs 2002 - 2009

Graph 3.1 Global revenues ($bn) for PD Drugs 2002 - 2009

• 3.21 Dopamine Agonists Dominate the PD Drug Treatment Market

Table 3.4 PD Drug Market Share, 2003

Chart 3.1 PD drug Market share, 2003

• 3.22 Sifrol is Leading Drug Treatment of PD

Table 3.5 Leading PD Drug Treatments

Table 3.6 Market Share for Da Agonists Vs Other Drugs

Chart 3.2 Market share for Da Agonists Versus Other Drugs

• 3.23 Current Surgical Therapy will not Become a Popular Treatment of PD
  • 3.23.1 Thalamotomy only used to Reduce Tremors
  • 3.23.2 Pallidotomy is Becoming a More Popular Treatment for PD
  • 3.23.3 Deep Brain Stimulation aids in Tremor Reduction
• 3.24 Emerging Therapies for PD Small Molecule Drugs
  • 3.24.2 Gene Therapy as a new Treatment Therapy
  • 3.24.3 Rasagiline
  • 3.24.4 Azilect
• 3.25 Other New Drugs in Development
  • 3.25.1 The Process of Apoptosis in PD
  • 3.25.2 Pig Neuron Implantations as New Treatments for PD
  • 3.25.3 A Nerve Growth May Have a Role in PD Treatment
  • 3.25.4 The Implantation of Dopamine Producing Cells as a Novel Therapy in PD
  • 3.25.5 GDNF Gene Therapy as a New Treatment Therapy
• 4. Alzheimer's Disease
  • 4.1 Introduction
  • 4.2 Symptoms and Differential Diagnosis
  • 4.3 The Risk Factors for AD
  • 4.4 The Demographics for AD

Chart 4.1 Percentage Share of People with AD Worldwide

• 4.5 The Financial Burden of AD
• 4.6 Type of Protein as a Cause for AD
  • 4.6.1 Neuronal and Synaptic Loss of AD
  • 4.6.2 Chromosomal Mutations of AD
  • 4.6.3 Inflammation of AD
• 4.7 Current AD Pharmaceutical Drug Therapies
  • 4.7.1 What is the AD market telling us?
• 4.8 Acetylcholinesterase - DHow do you Treat Mild to Moderate AD?
  • 4.8.1 Cognex (Tacrine)
  • 4.8.2 Aricept (Donepezil) - The Leading Choice for AD
  • 4.8.3 Reminyl (Galantamine) is a Minor Treatment for AD
• 4.9 The Drug Treatment for Moderate to Severe AD
• 4.10 Non Steroidal Anti-Inflammatory Drugs
• 4.11 The Market for AD Drugs Will See High Growth Rates

Table 4.1 Pharmaceutical Drug Treatment for AD

• 4.11.1 A Dramatic Climb for the AD Drug Market

Table 4.2 Market Forecast of AD 2002 - 2009

Graph 4.1 Market Forecast of AD 2002 - 2009

• 4.11.2 Market Will Show Hi Growth to 2009

Table 1.3 Market Share (%) of the Leading AD Drugs 2003, USA

Chart 4.2 Market Share (%) of the Leading AD Drugs, Q3 2003, USA

Table 4.4 World Revenues in AD Market 2002 - 2003

• 4.11.3 Aricept has High Sales Growth
• 4.11.4 Leading Cholinesterase Inhibitors in the AD Market

Table 4.6 World Market Share in AD Drug Market, Q3, 2003

Chart 4.4 World Market Share in AD Drug Market Q3, 2003

• 4.12 Emerging Therapies for AD
  • 4.12.1 Vitamin E (Antioxidants) for AD
  • 4.12.2 OTC Ginko Biloba May Slow AD Symptoms
  • 4.12.3 HRT May Protect Against AD
  • 4.12.4 Nicotine Replacement Therpay as a Potential Treatment for AD
• 4.13 Future Therapies for AD Will Not Overrule Conventional Drug Therapies
• 4.14 The Future Market for AD
• 4.15 Pipeline Drugs for AD
  • 4.15.1 PBT-1 (Coloquinol)
  • 4.15.2 Alzhemed
  • 4.15.3 Phenserine
• 4.16 The Future of the AD Drug Market
• 5. Multiple Sclerosis
  • 5.1 Introduction
  • 5.2 The Different Categories of MS
    • 5.2.1 Benign MS
    • 5.2.2 Relapse-remitting MS
    • 5.2.3 Primary progressive MS
    • 5.2.4 Secondary progressive
    • 5.2.5 Progressive relapsing MS
  • 5.3 Symptoms and Differential Diagnosis
    • 5.3.1 Primary symptoms
    • 5.3.2 Secondary symptoms
    • 5.3.3 Tertiary symptoms

Table 5.1 Breakdown of MS Symptoms

• 5.3.4 Diagnosis
• 5.4 The Risk factors of MS
  • 5.4.1 Immunologic Factors
  • 5.4.2 Environmental Effects May Influence MS Incidence
  • 5.4.3 The Viral Induction of MS is Possible
  • 5.4.4 The Genetic Influence of MS Exists
  • 5.4.5 Hormones Presidspose Women in MS
• 5.5 Demographics of MS

Table 5.2 The Worldwide Demographics of MS

• 5.6 Current Pharmaceutical Drug Therapies

Table 5.3 The Major Drug Treatments of MS, 2003

• 5.7 Relapse-Remitting MS
  • 5.7.1 Avonex (Interferon beta 1a) to reduce Severity of MS
  • 5.7.2 Rebif (Interferon beta 1b)
  • 5.7.3 Betaferon (Interferon beta 1b)
  • 5.7.4 Copaxone (Glatiramer acetate)
• 5.8 Antineoplastic Drugs [Relapse-Remitting & Secondary progressive]
  • 5.8.1 Cancer Drug, Novantrone (Mixonatrone) Benefits MS Sufferers
• 5.9 Taxanes
  • 5.9.1 Taxol (paclitaxel)
• 5.10 Immunosuppressants - Secondary Progressive and Worsening

Relapse-Remitting MS

• 5.10.1 Imuran (Azathioprine)
• 5.10.2 Sandimmune (Cyclosporine)
• 5.10.3 Methotrexate and Leustat
• 5.11 Corticosteroids
• 5.12 Muscle Relaxants
• 5.13 Avonex Remains the Leading MS Drug

Table 5.3 The Major Drug Treatments of MS

Table 5.4 Market Share of MS Drugs 2002 - 2003

Chart 5.2 Market share of MS Drugs

Table 5.5 Forecast of MS Drug Market 2002 - 2009

Graph 5.1 Forecast of MS Drug Market 2002 - 2009

Table 5.4 Market share of MS drugs 2002 and 2003

Chart 5.2 Market Share of Ms Drugs, 2003

Table 5.5 Forecast of Multiple Sclerosis Market, 2002 - 2009

Table 5.1 Forecast of Multiple Sclerosis Market 2002 - 2009

• 5.14 Pipeline drugs
  • 5.14.1 Antegren (Natalizumab)
  • 5.14.2 Leustat (Cladibrine)
• 5.15 Experimental Treatment for Multiple Sclerosis
  • 5.15.1 Gene Therapy
  • 5.15.2 Plasmapheresis (plasma exchange)
  • 5.15.3 Intravenous Immunoglobin (IVIg)
  • 5.15.4 Oligodendrocyte Implants
  • 5.15.5 Statins
• 6. Huntington's Disease
  • 6.1 Introduction
  • 6.2 Aetiology of HD
  • 6.3 Symptoms and Differential Diagnosis of HD
    • 6.3.1 Early Symptoms
    • 6.3.2 Advanced Symptoms
  • 6.4 Demographics of HD
  • 6.5 Pathophysiology of HD
  • 6.6 Current Pharmacological Treatment for HD
  • 6.7 Chorea controlled by Benzodiazepines
  • 6.8 Dopamine Antagonists can help HD patients
    • 6.8.1 Cannabinoids to Ease Symptoms of HD
  • 6.9 Monoamine-depleting agents
  • 6.10 Prospects for Future Treatment
    • 6.10.1 Cystamine to reduce symptoms
    • 6.10.2 HDAC Inhibitors may serve as a potential cure for HD
    • 6.10.3 The Case for Stem Cells
    • 6.10.4 Working on Neurotrophic Factors for HD
    • 6.10.5 Can Transglutaminase Inhibitors help in HD?
• 7. Amyotrophic Lateral Sclerosis
  • 7.1 Introduction
  • 7.2 The Progression of ALS
  • 7.3 Risk Factors
  • 7.4 Diagnosis
  • 7.5 The Demographic Impact of ALS
  • 7.6 What are the Treatment Options of ALS?
    • 7.6.1 Rilutek (riluzole)
    • 7.6.2 The Pharmacological Treatment for Symptom Relief of ALS
    • 7.6.3 Neurontin (Gabapentin)
    • 7.6.4 Topamax (Topiramate)
  • 7.7 Pipeline Drugs for ALS

Table 7.1 Current Drug Therpaies for ALS, 2003

• 7.7.1 Creatine Monohydrate
• 7.7.2 Xaliproden Hydrochloride
• 7.7.3 CEP 1347 (Cephalon's mixed-lineage kinase inhibitor)
• 7.8 Can a Cure be Found?
  • 7.8.1 Neurotrophic Factors
  • 7.8.2 The Role of Apoptosis in ALS
  • 7.8.3 Biological Markers for ALS
  • 7.8.4 Gene Research
  • 7.8.5 Minocycline
  • 7.8.6 Cox-2 (Nimesulide)
• 8. Neuropathies
  • 8.1 Introduction
  • 8.2 Causes of Neuropathy
  • 8.3 The Symptoms of Neuropathy
  • 8.4 Who is at Risk?
  • 8.5 Diagnosis of Neuropathy
  • 8.6 The Classifications of Neuropathy
    • 8.6.1 Diabetic Neuropathy
    • 8.6.2 Auto-Immune Disease Related and its Relationship with Neuropathic Pain
    • 8.6.3 Chemotherapy-Induced Neuropathy
    • 8.6.4 Drug-Related Neuropathy
  • 8.7 The Societal Impact of Neuropathy
  • 8.8 The Cost of Neuropathic Pain

Table 8.1 The Annual Cost of Pain

• 8.9 Current Treatment of Neuropathy
• 8.10 Non-pharmaceutical Treatments and Therapies
  • 8.10.1 Transcutaneous electronic nerve stimulation (TENS)
  • 8.10.2 Biofeedback
  • 8.10.3 Acupuncture
  • 8.10.4 Hypnosis
  • 8.10.5 Relaxation Techniques
• 8.12 The Major Current Pharmaceutical Treatment for Neuropathy
  • 8.12.1 Topical Agents
  • 8.12.2 Pain relievers
  • 8.12.3 Antidepressants

Table 8.2 Common Antidepressants used in treating Neuropathies

• 8.12.4 Anticonvulsants
• 8.12.5 Antiarrhythmics
• 8.12.6 Analgesics
• 8.13 Opioids maintaining relief for Neuropathy
  • 8.13.1 Morphine
  • 8.13.2 Fentanyl
  • 8.13.3 Oxycodone
• 8.14 Other Drugs used in Neuropathies
  • 8.14.1 Mexiletine
  • 8.14.2 Methycobal
  • 8.14.3 Tramadol
• 8.15 Current Developments: New Anticonvulsants
  • 8.15.1 Topiramate
  • 8.15.2 Lamotrigine
  • 8.15.3 Levetiracetam
• 8.16 New Developments: Aldose Reductase Inhibitors
  • 8.16.1 Thioctic Acid
• 8.17 Growth factors
• 8.18 NMDA antagonists

Table 8.3 New Developments in Drugs for Neuropathic Pain

• 9. Prion Diseases
  • 9.1 Introduction

Table 9.1 The Different Prion Diseases

• 9.2 CJD
  • 9.2.1 What is it?
  • 9.2.2 The Aetiology of CJD
• 9.3 Varying Types of CJD
  • 9.3.1 Sporadic or classical CJD
  • 9.3.2 Hereditary or familial CJD
  • 9.3.3 Acquired or iatrogenic aCJD
  • 9.3.4 (Variant) vCJD
• 9.4 Demographics of CJD
• 9.5 Symptoms of CJD
  • 9.5.1 Initial symptoms
  • 9.5.2 Progressive symptoms
  • 9.5.3 End-stage symptoms
• 9.6 Diagnosis of CJD
• 9.7 Treatments of CJD

Table 9.2 Pharmacological Treatments for CJD

• 9.8 The Political issues attached to CJD
• 9.9 Gerstmann-Straussler-Scheinker syndrome (GSS)
  • 9.9.1 What is it?
  • 9.9.2 Aetiology of GSS
  • 9.9.3 Symptoms of GSS
  • 9.9.4 Demographics of GSS
• 9.10 FFI
  • 9.10.1 Whats is it?
  • 9.10.2 Aetiology of FFI
  • 9.10.3 Symptoms of FFI
  • 9.10.4 Diagnosis of FFI
  • 9.10.5 Demographics of FFI
  • 9.10.6 Stages of FFI
  • 9.10.7 Treatment of FFI
• 9.11 Kuru
  • 9.11.1 What is it?
  • 9.11.2 Symptoms of Kuru
  • 9.11.3 Initial symptoms
  • 9.11.4 Secondary symptoms
  • 9.11.5 Demographics of Kuru
  • 9.11.6 Treatment of Kuru
  • 9.11.7 Future Research for Kuru
• 9.12 Alpers Syndrome
  • 9.12.1 What is it?
  • 9.12.2 Aetiology of Alpers
  • 9.12.3 Symptoms of Alpers
  • 9.12.4 Primary symptoms of Alpers
  • 9.12.5 Secondary symptoms of Alpers
  • 9.12.6 Treatment for Alper's Syndrome
  • 9.12.7 Prognosis of Alpers syndrome
  • 9.12.8 What research is being done?
• 10. Multiple Sclerosis Dominates the World Neurodegenerative Diseases Market

Other users found this report page using the following search terms: Neuroprotection neurodegeneration neurodegenerative alzheimers stroke parkinsons multiple sclerosis disease 2009 parkinsons graphs diseases market world graph neurodegeneratives sclerosis

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.